Zafgen Finds Plentiful Funding in Slimmed Down Obesity Market

The obesity-foucsed start-up Zafgen has emerged from stealth mode. Taking the reins as CEO is Thomas Hughes, PhD, former VP and global head of cardiovascular and metabolic disease at Novartis. With $22 million in funding from Atlas Venture and Third Rock Ventures, the company is well capitalized to drive its lead molecules into the clinic.